The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...
ABT gains momentum with strong FreeStyle Libre sales and Diagnostics growth but global macro headwinds weigh on performance.
Zacks Investment Research on MSN
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
Insulet PODD has seen impressive momentum in the past year, with its shares soaring 37.4%. It has significantly outperformed the industry’s 0.5% fall and the S&P 500 composite’s 17.5% gain. Presently ...
Biolinq announced today that it received FDA de novo clearance for its lead product, the Biolinq Shine wearable biosensor.
Biolinq Shine’s use of a microsensor array mitigates the need for an introducer needle for sensor placement as in traditional ...
Medical Device Network on MSN
Glooko acquires Monarch to advance diabetes platform reach
Glooko plans to develop an end-to-end ‘hospital-to-home’ care support provision for diabetes patients through the resources ...
L’analyste de UBS, Danielle Antalffy, a défendu l’action, déclarant que les vérifications auprès des médecins, les conversations avec la direction et les enquêtes récentes n’indiquent aucune ...
Le géant français du transport maritime et de la logistique CMA CGM a annoncé lundi acquérir le premier opérateur de fret ...
Coca-Cola ( KO -0.66%) and Abbott Laboratories ( ABT -0.43%) are two great examples along those lines. These two companies can offer stability and income to investors, as they belong to the exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback